The growing clinical interest in psilocybin for depression treatment has largely focused on its dramatic acute effects, but understanding its lasting neurological changes could unlock more precise therapeutic applications. This mechanistic discovery reveals how the brain continues processing psychedelic influence long after the subjective experience ends.
Rat brain slice experiments demonstrate that psilocin, psilocybin's active metabolite, creates persistent synaptic depression in the prelimbic cortex—a region critical for executive function and emotional regulation. This long-term depression occurs through an unexpected pathway: rather than acting primarily through the well-studied 5-HT2A receptors, psilocin enhances GABAergic inhibitory tone while requiring 5-HT1A receptor activity and neurotrophin signaling via TrkB receptors. The synaptic weakening persists beyond drug exposure and occurs equally in both male and female subjects.
This finding reframes our understanding of psychedelic neurobiology beyond the conventional 5-HT2A-centric model. The prelimbic cortex governs working memory, attention, and behavioral flexibility—functions often impaired in depression and anxiety disorders. Sustained synaptic depression in this region aligns with neuroimaging studies showing reduced prefrontal connectivity in humans after psilocybin administration. The involvement of TrkB receptors, which respond to brain-derived neurotrophic factor, suggests psilocin may leverage the same growth-promoting pathways targeted by conventional antidepressants, but through a fundamentally different mechanism. While promising for therapeutic development, this research raises important questions about cognitive side effects. The persistence of these neural changes, while potentially beneficial for breaking maladaptive thought patterns, might also impact executive functions that rely on robust prefrontal activity.